NEW YORK, Jan. 3, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Biologic Imaging Reagents: Technologies and Global Markets
http://www.reportlinker.com/p099465/Biologic-Imaging-Reagents-Technologies-and-Global-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging
STUDY GOALS AND OBJECTIVES
BCC's goal for this study was to determine the global market and future demand growth for biologic imaging reagents over a five-year period from 2012 to 2017. Our particular interest is to characterize and quantify the biologic imaging reagents market potential by technology, reagent type and end user market. We also evaluate future growth opportunities in emerging biologic imaging reagents including quantum dots, nanoparticles, fluorescent proteins and supermolecules.Imaging reagent types covered include fluorescent probes and dyes; fluorescent proteins; nanoparticles; magnetic resonance imaging, ultrasound and X-ray contrast reagents; and imaging radiopharmaceuticals.Our key objective was to present a comprehensive discussion of where the state-of-the-art is in biologic imaging reagents and forecast the future commercial potential for the key market segments. This discussion will provide a basis for companies to make strategic choices about developing new products and markets, or employing biologic imaging reagents. The study will benefit reagent and instrument manufacturers, users of biologic imaging reagents, medical instrument companies, life sciences tools companies, diagnostic and drug manufacturers, biotechnology companies, and developers of nanotechnologies.
REASONS FOR DOING THE STUDY
Biologic imaging reagents play an important role in the medical, pharmaceutical, diagnostic, biotechnology and life sciences tools industries. Imaging and detection technologies are used extensively in medicine, biotechnology and pharmaceutical research. Traditional imaging techniques, such as X-ray, computer tomography (CT), ultrasound (US), magnetic resonance imaging (MRI) and nuclear medicine (NM), mainly analyze anatomy and morphology and cannot detect changes at the molecular level. However, new developments in biotechnology allow us to image at the cellular and molecular level, paving the way for earlier diagnosis and treatment of disease. Biologic imaging reagents play a critical role in this medical revolution.At the same time, ongoing advances in genomics, proteomics and cellular analysis are aided by imaging technologies, including fluorescent dyes and probes, quantum dot nanoparticles, and fluorescent proteins. Growth in technologies such as biochips, DNA sequencing and polymerase chain reaction (PCR) relies on sensitive biologic fluorescent imaging reagents.Advances in technologies that are used in biologic imaging reagents are also moving forward at a rapid pace. These technologies include nanotechnology, biologic targeting, microfluidics, supramolecular chemistry and protein engineering. Rapid developments across a number of technology fields promise to change the biologic imaging industry by enabling novel imaging reagents and unique market opportunities. This report analyzes these developments and their impact on the future markets for biologic imaging reagents.Given these market and technology dynamics, it is especially timely to examine the biologic imaging reagents market.
CONTRIBUTION OF THE STUDY AND FOR WHOM
We have compiled a study of existing and future imaging reagent technologies that will be commercially important in the major end user segments, including life science research tools, drug discovery and development, and diagnostics.We present the various imaging reagent technologies, including fluorescent probes and dyes, nanomaterials, fluorescent proteins, contrast reagents, and imaging radiopharmaceuticals. We also examine the industry growth driving forces; product types; market applications; companies and industry alliances and acquisitions; future market potential; and product sales forecasts for the period 2012 through 2017. We project the future use of biologic imaging reagents in the main end user segments and by technology.This study will be of particular interest to life science research tools suppliers, pharmaceutical manufacturers, diagnostics, biotechnology, genomics, proteomics, nanotechnology and supramolecular companies. It will also be of interest to companies making products for medical imaging, microarrays, lab on a chip, polymerase chain reaction, molecular diagnostics assays, cell-based assays, and fluorescence activated cell sorting (FACS) as well as medical researchers and clinicians.
SCOPE AND FORMAT
The study scope includes the biologic imaging reagents that are commercial or likely to be commercialized within the next five years. Fluorescent probes and dyes; imaging nanomaterials (including quantum dots and other nanoparticles); fluorescent proteins; contrast reagents for MRI, X-ray and ultrasound; and imaging radiopharmaceuticals are studied. Both the in-vivo and in-vitro market segments are included. Each technology is analyzed to determine its market status, impact on future market segments and forecasted growth from 2012 through 2017. Technology status and market driving forces are also discussed.BCC examines imaging reagent producers and the industry structure in specialized segments of the industry. We also review industry alliances and acquisitions, and the use of biologic imaging reagents in key diagnostics and research and development (R&D) tools platforms, including microarrays, lab-on-a-chip devices, DNA sequencing, PCR and cellular analysis. The markets for novel biologic imaging reagent applications, including targeted multifunctional and hybrid therapeutic reagents, are analyzed, and the main companies in these fields are highlighted.
METHODOLOGY
BCC talked to key users and producers in the end user market segments and technology fields that will be commercially important during the next five years. Extensive secondary market research was performed.Based on our analysis, we project the future applications of biologic imaging reagents in the major end user market segments and by technology type and forecast sales revenues for 2012 through 2017.
INFORMATION SOURCES
BCC surveyed academic, government and industrial institutions to obtain data for this study. Included were life science research tools, pharmaceutical, diagnostic, biotechnology and nanotechnology firms, and leading life science research institutions. We also spoke with leading industry thought leaders. In addition, we compiled data from secondary sources, including industry, trade and government.
ANALYST CREDENTIALS
The author, John Bergin , has written numerous BCC biotechnology reports on genomics, microarrays, DNA sequencing, synthetic biology, epigenomics and diagnostics.Mr. Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company as well as executive management positions with an emerging separations company. Mr. Bergin holds the following degrees: B.S. Chemistry, M.S. Biotechnology and Masters of Business Administration.
REPORT HIGHLIGHTS
This report provides:- An overview of the global market for biologic imaging reagents, including those that are commercial or likely to be commercialized within the next five years- Analyses of global market trends, with data from 2011, estimates for 2012, and projections of compound annual growth rates (CAGRs) through 2017- Coverage of fluorescent probes and dyes; imaging nanomaterials (including quantum dots and other nanoparticles); fluorescent proteins; supermolecules; contrast reagents for MRI, X-ray and ultrasound; and imaging radiopharmaceuticals- Analysis of each technology to determine its market status and impact on future market segments- Discussion of imaging reagent producers and the industry structure in specialized segments- Reviews of industry alliances and acquisitions, and the use of biologic imaging reagents in key diagnostics and R&D tools platforms, including microarrays, lab-on-a-chip devices, DNA sequencing, PCR and cellular analysis- Comprehensive company profiles of major players in the industry.
TABLE OF CONTENTS CHAPTER 1 INTRODUCTION 1STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
CONTRIBUTION OF THE STUDY AND FOR WHOM 2
SCOPE AND FORMAT 2
METHODOLOGY 2
INFORMATION SOURCES 2
RELATED BCC REPORTS 3
ANALYST CREDENTIALS 3
BCC RESEARCH ONLINE SERVICES 3
DISCLAIMER 3
CHAPTER 2 EXECUTIVE SUMMARY 5SUMMARY TABLE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY CLASS, THROUGH2017 ($ MILLIONS) 5SUMMARY FIGURE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY CLASS,THROUGH 2017 ($ MILLIONS) 5
CHAPTER 3 OVERVIEW 9
INTRODUCTION 9
REPORT SCOPE 9
TABLE 1 SCOPE OF THIS REPORT 10
MARKET POTENTIAL 10
TABLE 2 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY CLASS,
THROUGH 2017 ($ MILLIONS) 10
TABLE 3 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY END USER MARKET,
THROUGH 2017 ($ MILLIONS) 11
INDUSTRY GROWTH DRIVING FORCES 12
TABLE 4 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES 12
LIFE CYCLE STATUS 14
TABLE 5 LIFE CYCLE STAGE OF BIOLOGIC IMAGING REAGENTS 14
BIOLOGIC IMAGING REAGENTS INDUSTRY 15
TABLE 6 BIOLOGIC IMAGING REAGENTS KEY COMPANIES 15
CHAPTER 4 BIOLOGIC IMAGING TECHNOLOGIES 17IMAGING REAGENT TYPES 17TABLE 7 KEY BIOLOGIC IMAGING REAGENT TYPES 17IN-VIVO IMAGING MODALITIES 18TABLE 8 IN-VIVO IMAGING MODALITIES 18TABLE 9 COMPARISON OF IN-VIVO IMAGING MODALITIES 19MOLECULAR IMAGING 20IN-VITRO IMAGING/DETECTION 21TABLE 10 APPLICATIONS OF IN-VITRO BIOLOGIC IMAGING 21TRENDS IN IN-VIVO IMAGING 21TABLE 11 KEY TECHNOLOGY DRIVERS FOR IN-VIVO IMAGING REAGENTS 22BIOLOGIC IMAGING REAGENTS TECHNOLOGIES 23NANOPARTICLES 23TABLE 12 NANOPARTICLES IN IMAGING APPLICATIONS 24FLUORESCENT DYES AND PROBES 25TABLE 13 FLUORESCENT DYES AND PROBES 25TABLE 14 GENERAL ADVANTAGES OF FLUORESCENCE LABELS 26TABLE 15 FLUORESCENT DYE PERFORMANCE CRITERIA 27FLUORESCENT PROTEINS 28TABLE 16 TYPES OF FLUORESCENT PROTEINS 28Genetically Engineered Fluorescent Proteins 29TABLE 17 PHOTOACTIVABLE AND PHOTOCONVERTIBLE FLUORESCENT PROTEIN TYPES 29Engineered Fluorescent Cell Lines 30Emerging Fluorescent Protein Applications 31TABLE 18 EMERGING APPLICATIONS OF FLUORESCENT PROTEINS 31Comparison of Fluorescent Proteins with Fluorescent Dyes 31TABLE 19 FLUORESCENT PROTEINS VERSUS DYES 32Technology Challenges 32TABLE 20 TECHNOLOGY CHALLENGES FOR FLUORESCENT PROTEINS 32SUPERMOLECULES 33TABLE 21 CLASSIFICATION OF IMAGING SUPERMOLECULES 33QUANTUM DOTS 34TABLE 22 COMPARISON OF QUANTUM DOTS, FLUORESCENT DYES AND FLUORESCENTPROTEINS 34FIGURE 1 QUANTUM DOT SPECTRA (INTENSITY) 35FIGURE 2 FLUORESCENT DYE SPECTRA 35TABLE 23 BIOLOGIC IMAGING APPLICATIONS OF QUANTUM DOTS 37RADIOPHARMACEUTICAL IMAGING REAGENTS 38CONTRAST IMAGING REAGENTS 38TABLE 24 MICROBUBBLE ULTRASOUND IMAGING AGENTS 40EMERGING CLASSES OF IMAGING REAGENTS 40COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY 40FIGURE 3 THREE COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY 41ADVANCED IMAGING REAGENT FUNCTIONS 42TABLE 25 EMERGING ADVANCED BIOLOGIC IMAGING REAGENT FUNCTIONS 42Dual Modality Reagents 42Multifunctional Reagents 42Multiplexed Reagents 43BIOLOGIC IMAGING REAGENTS MANUFACTURING COSTS 43FIGURE 4 ESTIMATED MANUFACTURING COSTS OF IMAGING REAGENTS CLASSES($/GRAM) 44COMPARISON OF IMAGING REAGENT TECHNOLOGY PLATFORMS 45TABLE 26 LIFE CYCLE OF BIOLOGIC IMAGING REAGENT TECHNOLOGIES 46TABLE 27 TECHNOLOGY STATUS OF BIOLOGIC IMAGING REAGENT PLATFORMS 47TABLE 28 TECHNOLOGY CHALLENGES FOR IN-VIVO IMAGING REAGENTS 48
CHAPTER 5 BIOLOGIC IMAGING REAGENTS APPLICATIONS 50
OVERVIEW 50
TABLE 29 BIOLOGIC IMAGING REAGENTS APPLICATIONS 50
TABLE 30 SIGNIFICANCE OF BIOLOGIC IMAGING REAGENTS TO LIFE SCIENCES AND
MEDICAL INDUSTRIES 51
TABLE 31 USE OF BIOLOGIC IMAGING REAGENTS BY MARKET SEGMENT 52
TABLE 32 APPLICATIONS WITHIN MARKET SEGMENTS 52
RESEARCH AND DEVELOPMENT 53
TABLE 33 R&D TOOLS IMAGING REAGENTS 53
TABLE 34 EMERGING APPLICATIONS FOR BIOLOGIC IMAGING REAGENTS IN R&D TOOLS 54
DRUG DISCOVERY AND DEVELOPMENT 54
TABLE 35 IMAGING APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 55
INFLUENCE OF IMAGING TECHNOLOGY ON DRUG DEVELOPMENT 55
ATTRITION RATE OF LEAD DRUG COMPOUNDS 56
FIGURE 5 ATTRITION RATE OF DRUG CANDIDATES DURING DRUG DEVELOPMENT 57
FLUORESCENT PROTEIN APPLICATIONS IN DRUG DISCOVERY 57
IN-VIVO SMALL ANIMAL IMAGING APPLICATIONS 58
TABLE 36 COMPARISON OF SMALL ANIMAL IMAGING MODALITIES 58
TABLE 37 OUTSTANDING MARKET NEEDS FOR SMALL ANIMAL IMAGING 59
DIAGNOSTICS 59
INTRODUCTION 59
TABLE 38 DIAGNOSTICS IMAGING REAGENTS APPLICATIONS 60
DIAGNOSTIC APPLICATIONS OF IMAGING REAGENTS 60
TABLE 39 DIAGNOSTIC APPLICATIONS OF SELECTED IMAGING REAGENTS 61
Fluorescent Dyes, Probes and Tags 61
Nanoparticles 61
Supermolecules 62
Imaging Radiopharmaceuticals 62
Contrast Reagents 62
MOLECULAR IMAGING 63
TABLE 40 CLINICAL APPLICATIONS FOR IN VIVO MOLECULAR IMAGING 63
CHAPTER 6 BIOLOGIC IMAGING REAGENTS INDUSTRY STRUCTURE 66INNOVATION WITHIN THE IMAGING REAGENT INDUSTRY 66STRATEGIC ALLIANCES 66TABLE 41 BIOLOGIC IMAGING REAGENT STRATEGIC ALLIANCES, 2010-2012 67INDUSTRY ACQUISITIONS 70TABLE 42 BIOLOGIC IMAGING REAGENTS INDUSTRY ACQUISITIONS, 2010–2012 71MEDICAL IMAGING INSTRUMENT SECTOR 72TABLE 43 COMPETITIVE FOCUS OF MAJOR MEDICAL IMAGING COMPANIES 73FLUORESCENT DYES AND PROBES INDUSTRY STRUCTURE 73TABLE 44 FLUORESCENT IMAGING REAGENTS COMPETITORS 74QUANTUM DOTS INDUSTRY 75TABLE 45 QUANTUM DOT COMPETITORS 75CONTRAST REAGENTS INDUSTRY 76TABLE 46 CONTRAST AGENTS KEY COMPETITORS 77RADIOPHARMACEUTICALS INDUSTRY 77TABLE 47 IMAGING RADIOPHARMACEUTICALS COMPANIES 77TABLE 48 RADIOPHARMACEUTICALS BIOTECHNOLOGY COMPANIES 79RADIOACTIVE ISOTOPES SUPPLY 80SMALL ANIMAL IN-VIVO IMAGING INDUSTRY 80TABLE 49 SMALL ANIMAL IN-VIVO FUNCTIONAL IMAGING REAGENT COMPETITORS 81CARDIAC IMAGING INDUSTRY 82TABLE 50 CARDIAC IMAGING REAGENT COMPETITIVE SPACE 82PROSTATE CANCER IMAGING INDUSTRY 84TABLE 51 PROSTATE CANCER IMAGING AGENT COMPETITION 84ALZHEIMER'S DISEASE PET IMAGING INDUSTRY 85TABLE 52 ALZHEIMER'S DISEASE PET IMAGING AGENT COMPETITIVE SPACE 85
CHAPTER 7 BIOLOGIC IMAGING REAGENTS MARKETS 88
GROWTH DRIVING FORCES 88
TABLE 53 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES 88
MARKET OVERVIEW 90
TABLE 54 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY APPLICATION, THROUGH
2017 ($ MILLIONS) 90
TABLE 55 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY CLASS,
THROUGH 2017 ($ MILLIONS) 91
TABLE 56 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS MARKET, BY END USE,
THROUGH 2017 ($ MILLIONS) 92
TABLE 57 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY END USER MARKET,
THROUGH 2017 ($ MILLIONS) 92
TABLE 58 GLOBAL VALUE OF BIOLOGIC REAGENTS MARKET, BY MODALITY, THROUGH
2017 ($ MILLIONS) 93
CONTRAST REAGENTS MARKET 94
TABLE 59 GLOBAL VALUE OF CONTRAST REAGENTS MARKET, BY MODALITY, THROUGH
2017 ($ MILLIONS) 94
MRI REAGENTS MARKET 95
TABLE 60 GLOBAL VALUE OF MRI REAGENTS MARKET, BY TYPE, THROUGH 2017 ($
MILLIONS) 95
TABLE 61 GLOBAL VALUE OF GD-CHELATE MRI REAGENTS BY PRODUCT, THROUGH 2017 ($
MILLIONS) 96
TABLE 62 GLOBAL VALUE OF MRI NON-GD CHELATE REAGENTS, THROUGH 2017 ($
MILLIONS) 98
TABLE 63 GLOBAL SALES OF MRI CONTRAST REAGENTS BY PROCEDURE, THROUGH 2017
($ MILLIONS) 99
ULTRASOUND REAGENTS MARKET 99
TABLE 64 GLOBAL VALUE OF MICROBUBBLE ULTRASOUND REAGENTS MARKET, BY TYPE,
THROUGH 2017 ($ MILLIONS) 99
X-RAY/CT REAGENTS MARKET 100
TABLE 65 GLOBAL VALUE OF X-RAY/CT REAGENTS MARKET, BY TYPE, THROUGH 2017 ($
MILLIONS) 101
TABLE 66 GLOBAL VALUE OF X-RAY/CT REAGENTS MARKET, BY INDICATION, THROUGH
2017 ($ MILLIONS) 102
RADIOPHARMACEUTICALS MARKET 102
TABLE 67 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY
SCANNER TYPE, THROUGH 2017 ($ MILLIONS) 102
TABLE 68 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY
ISOTOPE, THROUGH 2017 ($ MILLIONS) 103
TABLE 69 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY
INDICATION, THROUGH 2017 ($ MILLIONS) 104
TABLE 70 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY
TECHNOLOGY, THROUGH 2017 ($ MILLIONS) 105
SPECT RADIOPHARMACEUTICALS MARKET 106
TABLE 71 GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY ISOTOPE, THROUGH
2017 ($ MILLIONS) 106
TABLE 72 HALF LIFE OF COMMON PET AND SPECT ISOTOPES 107
TABLE 73 GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY INDICATION,
THROUGH 2017 ($ MILLIONS) 107
TABLE 74 SENTINEL NODE DETECTION RADIOPHARMACEUTICALS PRODUCERS 108
TABLE 75 GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY TECHNOLOGY,
THROUGH 2017 ($ MILLIONS) 109
PET RADIOPHARMACEUTICALS MARKET 109
TABLE 76 GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY ISOTOPE, THROUGH
2017 ($ MILLIONS) 110
TABLE 77 GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY INDICATION,
THROUGH 2017 ($ MILLIONS) 110
TABLE 78 GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY TECHNOLOGY,
THROUGH 2017 ($ MILLIONS) 112
OPTICAL IMAGING REAGENTS MARKET 112
TABLE 79 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY
APPLICATION, THROUGH 2017 ($ MILLIONS) 112
TABLE 80 GLOBAL VALUE OF IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS
MARKET, BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 113
TABLE 81 GLOBAL VALUE OF GENOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING
REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 114
TABLE 82 GLOBAL VALUE OF PROTEOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING
REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 115
TABLE 83 GLOBAL VALUE OF CELLULAR ANALYSIS IN-VITRO OPTICAL FLUORESCENT
IMAGING REAGENTS MARKET BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 116
TABLE 84 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS, BY END USE,
THROUGH 2017 ($ MILLIONS) 116
TABLE 85 GLOBAL VALUE OF IN-VITRO OPTICAL IMAGING REAGENTS, BY TYPE, THROUGH
2017 ($ MILLIONS) 117
GEOGRAPHICAL MARKET 118
TABLE 86 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY GEOGRAPHY, THROUGH
2017 ($ MILLIONS) 118
CHAPTER 8 PATENT STATUS 121IMAGING REAGENTS PATENTS BY SELECTED TECHNOLOGY 121TABLE 87 NUMBER OF PATENTS BY TECHNOLOGY, 2001-2011 121FLUORESCENCE REAGENTS 122TABLE 88 FLUORESCENCE REAGENTS PATENT ASSIGNEES BY COMPANY (NO.) 122FLUORESCENT PROTEINS 123TABLE 89 FLUORESCENT PROTEIN PATENT ASSIGNEES BY COMPANY (NO.) 123QUANTUM DOTS 123TABLE 90 QUANTUM DOTS PATENT ASSIGNEES BY COMPANY (NO.) 123GOLD NANOPARTICLES 124TABLE 91 GOLD NANOPARTICLE PATENT ASSIGNEES BY COMPANY (NO.) 124SUMMARY OF PATENTS BY COMPANY 125TABLE 92 NUMBER OF PATENTS, BY COMPANY, FOR FOUR IMAGING REAGENT MARKETSEGMENTS 125
CHAPTER 9 COMPANY PROFILES 127
ABT MOLECULAR IMAGING INC. 127
ABX ADVANCED BIOCHEMICAL COMPOUNDS GMBH 127
ACTIVE MOTIF CHROMEON GMBH 127
ACUSPHERE INC. 128
ADVANCED ACCELERATOR APPLICATIONS SA 128
ADVANCED PROTEOME THERAPEUTICS INC. 129
ADVANCED RESEARCH TECHNOLOGIES, INC. 129
AFFIBODY AB 130
TABLE 93 AFFIBODY ALLIANCES 130
AGENIX LTD. 131
ALSERES PHARMACEUTICALS INC. 131
ALZHYME PTY LTD. 132
AMAG PHARMACEUTICALS INC. 132
AMERICAN ELEMENTS 133
AMERICAN DYE SOURCE INC. 133
ANASPEC INC. 134
ANTICANCER INC. 134
APOSENSE 135
AREVA 135
ASTELLAS PHARMA INC. 136
ASTRAZENECA LTD. 136
ATREUS PHARMACEUTICALS CORPORATION 137
ATTO-TEC GMBH 137
AXXAM SPA 137
BAYER HEALTHCARE AG 138
BBI INTERNATIONAL 138
BD 139
BECKMAN COULTER INC. 140
BETAPLUS RADIOPHARMACEUTIALS LLC 140
BIOFORCE NANOSCIENCES HOLDINGS INC. 141
BIOMODA INC. 141
BIOSCAN INC. 142
BIOSEARCH TECHNOLOGIES INC. 142
BIOSCEPTRE INTERNATIONAL LIMITED 143
BIOTIUM INC. 143
BIOVISION, INC. 143
BRACCO IMAGING S.P.A. 144
CAPSULUTION PHARMA AG 145
CARDINAL HEALTH 146
CARESTREAM HEALTH INC. 146
CELLCYTE GENETICS 147
CELLPOINT LLC. 147
CHEMATECH SAS 148
CHEMICELL GMBH 148
CHINA MEDICAL TECHNOLOGIES INC. 148
CHROMOTEK GMBH 149
CISBIO BIOASSAYS 149
COVALYS BIOSCIENCES AG 150
COVIDIEN PLC 150
CYTODIAGNOSTICS 151
DAIICHI SANKYO CO. LTD. 151
DENDRITECH INC. 151
DENOVO BIOLABELS GMBH 152
EBIOSCIENCE INC. 152
ECKERT & ZIEGLER AG 152
ELI LILLY AND COMPANY 153
ERIGAL LIMITED 154
ESTECH PHARMA CO. LTD. 154
EVIDENT TECHNOLOGIES 155
EVROGEN 155
FERROPHARM GMBH 156
FLUOPTICS 156
FLUOROPHARMA INC. 157
TABLE 94 FLUORPHARMA PET IMAGING REAGENT PIPELINE 157
FUJI PHARMA CO. LTD. 158
GE HEALTHCARE 158
GENISPHERE LLC 159
GUERBET 160
IASON GMBH 160
IMAGINAB INC. 160
IMMUNOMEDICS INC. 161
INDEC BIOSYSTEMS 162
INNOPROT 162
INVISAGE INC. 162
IPSEN GROUP 163
ISO-TEX DIAGNOSTICS INC. 163
JAZZ PHARMACEUTICALS PLC 163
J.B. CHEMICALS & PHARMACEUTICALS LTD. 164
JOHNSON & JOHNSON 164
JUBILANT LIFE SCIENCES LTD. 165
KEREOS INC. 165
TABLE 95 KEREOS IMAGING REAGENTS PIPELINE 165
KPL INC. 166
LAB21 LTD 167
LABORATOIRES CYCLOPHARMA 167
LANTHEUS MEDICAL IMAGING 167
TABLE 96 LANTHEUS DIAGNOSTIC IMAGING PIPELINE 168
LIFE TECHNOLOGIES INC. 169
LUMIPHORE INC. 170
LUNA NANOWORKS 170
MARINPHARM GMBH 171
MARVAL BIOSCIENCES INC. 171
MBL INTERNATIONAL 172
MEDI RADIOPHARMA LTD 172
MELLITECH SAS 172
MOBIOTEC GMBH 173
MOLECULAR INSIGHT PHARMACEUTICALS 173
TABLE 97 MOLECULAR INSIGHT IMAGING REAGENTS PIPELINE 173
MOLECULAR TARGETING TECHNOLOGIES INC. 174
NANOAXIS LLC 175
NANOCO TECHNOLOGIES LTD. 175
NANO-H SAS 176
NANOPROBES INC. 176
NANOSCAN IMAGING LLC 177
TABLE 98 LYMPH NODE STATUS 177
NANOSPECTRA BIOSCIENCES 177
NANOSPHERE INC. 178
TABLE 99 NANOSPHERE GOLD IMAGING REAGENTS PIPELINE 179
NAVIDEA BIOPHARMACEUTICALS 179
TABLE 100 NAVIDEA PIPELINE 180
NN-LABS LLC 181
NORDION INC. 181
NOVELOS THERAPEUTICS INC. 182
NUVIEW LIFE SCIENCES 182
OCEAN NANOTECH LLC 182
OCTREOPHARM SCIENCES GMBH 183
OXFORD CONTRAST MOLECULAR DIAGNOSTICS 183
OXONICA INC. 184
PERKINELMER INC. 184
PHARMALUCENCE INC. 186
PHILIPS HEALTHCARE 186
PHOTOCURE ASA 187
PIRAMAL HEALTHCARE LTD. 188
PRINCIPIO, INC. 188
PROMEGA CORPORATION 189
QUANTUM MATERIALS CORPORATION 189
RAPIDSCAN PHARMA SOLUTIONS INC. 190
READE ADVANCED MATERIALS 190
SIEMENS AG 190
SIRIGEN LTD. 191
SIGNALOMICS GMBH 191
SPAGO IMAGING AB 192
SOFIE BIOSCIENCES 192
TAKARA BIO INC. 193
TAEJOON PHARMA CO. LTD. 193
TARGESON INC. 194
THERAGNOSTIC TECHNOLOGIES INC. 194
THERMO FISHER SCIENTIFIC 194
TK-SIGNAL LTD. 196
TOP SRL 196
WILEX AG 196
TABLE 101 WILEX CLINICAL PRODUCT PIPELINE 197
LIST OF TABLES SUMMARY TABLE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY CLASS, THROUGH2017 ($ MILLIONS) 5
TABLE 1 SCOPE OF THIS REPORT 10
TABLE 2 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY CLASS,
THROUGH 2017 ($ MILLIONS) 10
TABLE 3 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY END USER MARKET,
THROUGH 2017 ($ MILLIONS) 11
TABLE 4 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES 12
TABLE 5 LIFE CYCLE STAGE OF BIOLOGIC IMAGING REAGENTS 14
TABLE 6 BIOLOGIC IMAGING REAGENTS KEY COMPANIES 15
TABLE 7 KEY BIOLOGIC IMAGING REAGENT TYPES 17
TABLE 8 IN-VIVO IMAGING MODALITIES 18
TABLE 9 COMPARISON OF IN-VIVO IMAGING MODALITIES 19
TABLE 10 APPLICATIONS OF IN-VITRO BIOLOGIC IMAGING 21
TABLE 11 KEY TECHNOLOGY DRIVERS FOR IN-VIVO IMAGING REAGENTS 22
TABLE 12 NANOPARTICLES IN IMAGING APPLICATIONS 24
TABLE 13 FLUORESCENT DYES AND PROBES 25
TABLE 14 GENERAL ADVANTAGES OF FLUORESCENCE LABELS 26
TABLE 15 FLUORESCENT DYE PERFORMANCE CRITERIA 27
TABLE 16 TYPES OF FLUORESCENT PROTEINS 28
TABLE 17 PHOTOACTIVABLE AND PHOTOCONVERTIBLE FLUORESCENT PROTEIN TYPES 29
TABLE 18 EMERGING APPLICATIONS OF FLUORESCENT PROTEINS 31
TABLE 19 FLUORESCENT PROTEINS VERSUS DYES 32
TABLE 20 TECHNOLOGY CHALLENGES FOR FLUORESCENT PROTEINS 32
TABLE 21 CLASSIFICATION OF IMAGING SUPERMOLECULES 33
TABLE 22 COMPARISON OF QUANTUM DOTS, FLUORESCENT DYES AND FLUORESCENT
PROTEINS 34
TABLE 23 BIOLOGIC IMAGING APPLICATIONS OF QUANTUM DOTS 37
TABLE 24 MICROBUBBLE ULTRASOUND IMAGING AGENTS 40
TABLE 25 EMERGING ADVANCED BIOLOGIC IMAGING REAGENT FUNCTIONS 42
TABLE 26 LIFE CYCLE OF BIOLOGIC IMAGING REAGENT TECHNOLOGIES 46
TABLE 27 TECHNOLOGY STATUS OF BIOLOGIC IMAGING REAGENT PLATFORMS 47
TABLE 28 TECHNOLOGY CHALLENGES FOR IN-VIVO IMAGING REAGENTS 48
TABLE 29 BIOLOGIC IMAGING REAGENTS APPLICATIONS 50
TABLE 30 SIGNIFICANCE OF BIOLOGIC IMAGING REAGENTS TO LIFE SCIENCES AND
MEDICAL INDUSTRIES 51
TABLE 31 USE OF BIOLOGIC IMAGING REAGENTS BY MARKET SEGMENT 52
TABLE 32 APPLICATIONS WITHIN MARKET SEGMENTS 52
TABLE 33 R&D TOOLS IMAGING REAGENTS 53
TABLE 34 EMERGING APPLICATIONS FOR BIOLOGIC IMAGING REAGENTS IN R&D TOOLS 54
TABLE 35 IMAGING APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT 55
TABLE 36 COMPARISON OF SMALL ANIMAL IMAGING MODALITIES 58
TABLE 37 OUTSTANDING MARKET NEEDS FOR SMALL ANIMAL IMAGING 59
TABLE 38 DIAGNOSTICS IMAGING REAGENTS APPLICATIONS 60
TABLE 39 DIAGNOSTIC APPLICATIONS OF SELECTED IMAGING REAGENTS 61
TABLE 40 CLINICAL APPLICATIONS FOR IN VIVO MOLECULAR IMAGING 63
TABLE 41 BIOLOGIC IMAGING REAGENT STRATEGIC ALLIANCES, 2010-2012 67
TABLE 42 BIOLOGIC IMAGING REAGENTS INDUSTRY ACQUISITIONS, 2010–2012 71
TABLE 43 COMPETITIVE FOCUS OF MAJOR MEDICAL IMAGING COMPANIES 73
TABLE 44 FLUORESCENT IMAGING REAGENTS COMPETITORS 74
TABLE 45 QUANTUM DOT COMPETITORS 75
TABLE 46 CONTRAST AGENTS KEY COMPETITORS 77
TABLE 47 IMAGING RADIOPHARMACEUTICALS COMPANIES 77
TABLE 48 RADIOPHARMACEUTICALS BIOTECHNOLOGY COMPANIES 79
TABLE 49 SMALL ANIMAL IN-VIVO FUNCTIONAL IMAGING REAGENT COMPETITORS 81
TABLE 50 CARDIAC IMAGING REAGENT COMPETITIVE SPACE 82
TABLE 51 PROSTATE CANCER IMAGING AGENT COMPETITION 84
TABLE 52 ALZHEIMER'S DISEASE PET IMAGING AGENT COMPETITIVE SPACE 85
TABLE 53 BIOLOGIC IMAGING REAGENTS GROWTH DRIVING FORCES 88
TABLE 54 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY APPLICATION, THROUGH
2017 ($ MILLIONS) 90
TABLE 55 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY TECHNOLOGY CLASS,
THROUGH 2017 ($ MILLIONS) 91
TABLE 56 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS MARKET, BY END USE,
THROUGH 2017 ($ MILLIONS) 92
TABLE 57 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY END USER MARKET,
THROUGH 2017 ($ MILLIONS) 92
TABLE 58 GLOBAL VALUE OF BIOLOGIC REAGENTS MARKET, BY MODALITY, THROUGH 2017
($ MILLIONS) 93
TABLE 59 GLOBAL VALUE OF CONTRAST REAGENTS MARKET, BY MODALITY, THROUGH 2017
($ MILLIONS) 94
TABLE 60 GLOBAL VALUE OF MRI REAGENTS MARKET, BY TYPE, THROUGH 2017 ($
MILLIONS) 95
TABLE 61 GLOBAL VALUE OF GD-CHELATE MRI REAGENTS BY PRODUCT, THROUGH 2017 ($
MILLIONS) 96
TABLE 62 GLOBAL VALUE OF MRI NON-GD CHELATE REAGENTS, THROUGH 2017 ($
MILLIONS) 98
TABLE 63 GLOBAL SALES OF MRI CONTRAST REAGENTS BY PROCEDURE, THROUGH 2017 ($
MILLIONS) 99
TABLE 64 GLOBAL VALUE OF MICROBUBBLE ULTRASOUND REAGENTS MARKET, BY TYPE,
THROUGH 2017 ($ MILLIONS) 99
TABLE 65 GLOBAL VALUE OF X-RAY/CT REAGENTS MARKET, BY TYPE, THROUGH 2017 ($
MILLIONS) 101
TABLE 66 GLOBAL VALUE OF X-RAY/CT REAGENTS MARKET, BY INDICATION, THROUGH 2017
($ MILLIONS) 102
TABLE 67 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY
SCANNER TYPE, THROUGH 2017 ($ MILLIONS) 102
TABLE 68 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY
ISOTOPE, THROUGH 2017 ($ MILLIONS) 103
TABLE 69 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY
INDICATION, THROUGH 2017 ($ MILLIONS) 104
TABLE 70 GLOBAL VALUE OF RADIOPHARMACEUTICALS IMAGING REAGENTS MARKET, BY
TECHNOLOGY, THROUGH 2017 ($ MILLIONS) 105
TABLE 71 GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY ISOTOPE, THROUGH
2017 ($ MILLIONS) 106
TABLE 72 HALF LIFE OF COMMON PET AND SPECT ISOTOPES 107
TABLE 73 GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY INDICATION,
THROUGH 2017 ($ MILLIONS) 107
TABLE 74 SENTINEL NODE DETECTION RADIOPHARMACEUTICALS PRODUCERS 108
TABLE 75 GLOBAL VALUE OF SPECT IMAGING REAGENTS MARKET, BY TECHNOLOGY,
THROUGH 2017 ($ MILLIONS) 109
TABLE 76 GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY ISOTOPE, THROUGH
2017 ($ MILLIONS) 110
TABLE 77 GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY INDICATION, THROUGH
2017 ($ MILLIONS) 110
TABLE 78 GLOBAL VALUE OF PET IMAGING REAGENTS MARKET, BY TECHNOLOGY,
THROUGH 2017 ($ MILLIONS) 112
TABLE 79 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS MARKET, BY
APPLICATION, THROUGH 2017 ($ MILLIONS) 112
TABLE 80 GLOBAL VALUE OF IN-VITRO OPTICAL FLUORESCENT IMAGING REAGENTS
MARKET, BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 113
TABLE 81 GLOBAL VALUE OF GENOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING
REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 114
TABLE 82 GLOBAL VALUE OF PROTEOMICS IN-VITRO OPTICAL FLUORESCENT IMAGING
REAGENTS MARKET, BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 115
TABLE 83 GLOBAL VALUE OF CELLULAR ANALYSIS IN-VITRO OPTICAL FLUORESCENT
IMAGING REAGENTS MARKET BY ASSAY TYPE, THROUGH 2017 ($ MILLIONS) 116
TABLE 84 GLOBAL VALUE OF OPTICAL FLUORESCENT IMAGING REAGENTS, BY END USE,
THROUGH 2017 ($ MILLIONS) 116
TABLE 85 GLOBAL VALUE OF IN-VITRO OPTICAL IMAGING REAGENTS, BY TYPE, THROUGH
2017 ($ MILLIONS) 117
TABLE 86 GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS, BY GEOGRAPHY, THROUGH
2017 ($ MILLIONS) 118
TABLE 87 NUMBER OF PATENTS BY TECHNOLOGY, 2001-2011 121
TABLE 88 FLUORESCENCE REAGENTS PATENT ASSIGNEES BY COMPANY (NO.) 122
TABLE 89 FLUORESCENT PROTEIN PATENT ASSIGNEES BY COMPANY (NO.) 123
TABLE 90 QUANTUM DOTS PATENT ASSIGNEES BY COMPANY (NO.) 123
TABLE 91 GOLD NANOPARTICLE PATENT ASSIGNEES BY COMPANY (NO.) 124
TABLE 92 NUMBER OF PATENTS, BY COMPANY, FOR FOUR IMAGING REAGENT MARKET
SEGMENTS 125
TABLE 93 AFFIBODY ALLIANCES 130
TABLE 94 FLUORPHARMA PET IMAGING REAGENT PIPELINE 157
TABLE 95 KEREOS IMAGING REAGENTS PIPELINE 165
TABLE 96 LANTHEUS DIAGNOSTIC IMAGING PIPELINE 168
TABLE 97 MOLECULAR INSIGHT IMAGING REAGENTS PIPELINE 173
TABLE 98 LYMPH NODE STATUS 177
TABLE 99 NANOSPHERE GOLD IMAGING REAGENTS PIPELINE 179
TABLE 100 NAVIDEA PIPELINE 180
TABLE 101 WILEX CLINICAL PRODUCT PIPELINE 197
LIST OF FIGURES SUMMARY FIGURE GLOBAL VALUE OF BIOLOGIC IMAGING REAGENTS BY CLASS, THROUGH2017 ($ MILLIONS) 5
FIGURE 1 QUANTUM DOT SPECTRA (INTENSITY) 35
FIGURE 2 FLUORESCENT DYE SPECTRA 35
FIGURE 3 THREE COMPONENTS OF ADVANCED IMAGING REAGENT TECHNOLOGY 41
FIGURE 4 ESTIMATED MANUFACTURING COSTS OF IMAGING REAGENTS CLASSES ($/GRAM) 44
FIGURE 5 ATTRITION RATE OF DRUG CANDIDATES DURING DRUG DEVELOPMENT 57
To order this report:Medical_Imaging Industry: Biologic Imaging Reagents: Technologies and Global MarketsCONTACT
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
RELATED LINKS
http://www.reportlinker.com
Source: www.prnewswire.com
No comments:
Post a Comment